Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLA known ✓ | P06280 | 2/20 | 0.43 |
| ▸ | GAA known ✓ | P10253 | 2/20 | 0.43 |
| ▸ | GBA1 | P04062 | 10/20 | 0.96 |
| ▸ | FUCA1 | P04066 | 4/20 | 0.43 |
| ▸ | GLB1 | P16278 | 1/20 | 0.43 |
| ▸ | PYGL | P06737 | 1/20 | 0.38 |
| ▸ | GBA2 | Q9HCG7 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL20582653 | 1.00 | GBA1 (0.96) | GBA1FUCA1GLAGAAGLB1 | |
| Hydrochloric Acid SCHEMBL1651911 | 1.00 | GBA1 (0.96) | GBA1FUCA1GLAGAAGLB1 | |
| Hydrochloric Acid SCHEMBL20561370 | 1.00 | GBA1 (0.96) | GBA1FUCA1GLAGAAGLB1 | |
| Hydrochloric Acid SCHEMBL27867104 | 1.00 | GBA1 (0.96) | GBA1FUCA1GLAGAAGLB1 | |
| Hydrochloric Acid SCHEMBL27867105 | 1.00 | GBA1 (0.96) | GBA1FUCA1GLAGAAGLB1 | |
| SCHEMBL6857545 | 0.98 | GBA1 (1.00) | GBA1FUCA1GLAGAAGLB1 | |
| SCHEMBL6857546 | 0.98 | GBA1 (1.00) | GBA1FUCA1GLAGAAGLB1 | |
| Hydrochloric Acid SCHEMBL1629572 | 0.79 | GBA1 (0.96) | GBA1FUCA1GLAGAAGLB1 | |
| Hydrochloric Acid SCHEMBL1627927 | 0.79 | GBA1 (0.96) | GBA1FUCA1GLAGAAGLB1 | |
| Hydrochloric Acid SCHEMBL1627488 | 0.79 | GBA1 (0.96) | GBA1FUCA1GLAGAAGLB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8604057-B2 | Compositions for preventing and/or treating lysosomal storage disorders | AMICUS THERAPEUTICS, INC. (US) | 2013-12-10 | — | — | US | claimed |
| EP-3143875-B1 | NOVEL COMPOSITIONS FOR PREVENTING AND/OR TREATING DEGENERATIVE DISORDERS OF THE CENTRAL NERVOUS SYSTEM | AMICUS THERAPEUTICS INC (US) | 2020-05-27 | — | — | EP | disclosed |
| US-10421724-B2 | Compositions for preventing and/or treating degenerative disorders of the central nervous system | AMICUS THERAPEUTICS, INC. (US) | 2019-09-24 | — | — | US | disclosed |
| EP-2995306-B1 | NOVEL COMPOSITIONS FOR PREVENTING AND/OR TREATING LYSOSOMAL STORAGE DISORDERS | AMICUS THERAPEUTICS INC (US) | 2018-12-19 | — | — | EP | disclosed |
| US-20180334432-A1 | Novel Compositions for Preventing and/or Treating Lysosomal Storage Disorders | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2018-11-22 | — | — | US | disclosed |
| US-20180273474-A1 | Novel Compositions For Preventing And/Or Treating Degenerative Disorders Of The Central Nervous System | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2018-09-27 | — | — | US | disclosed |
| US-10035766-B2 | Compositions for preventing and/or treating lysosomal storage disorders | AMICUS THERAPEUTICS, INC. (US) | 2018-07-31 | — | — | US | disclosed |
| EP-3143875-A1 | NOVEL COMPOSITIONS FOR PREVENTING AND/OR TREATING DEGENERATIVE DISORDERS OF THE CENTRAL NERVOUS SYSTEM | Amicus Therapeutics, Inc. (US) | 2017-03-22 | — | — | EP | disclosed |
| EP-2490532-B1 | NOVEL COMPOSITIONS FOR PREVENTING AND/OR TREATING DEGENERATIVE DISORDERS OF THE CENTRAL NERVOUS SYSTEM | AMICUS THERAPEUTICS INC (US) | 2016-11-23 | — | — | EP | disclosed |
| US-20160326114-A1 | NOVEL COMPOSITIONS FOR PREVENTING AND/OR TREATING DEGENERATIVE DISORDERS OF THE CENTRAL NERVOUS SYSTEM | AMICUS THERAPEUTICS, INC. (US) | 2016-11-10 | — | — | US | disclosed |
| US-20140086896-A1 | Novel Compositions for Preventing and/or Treating Lysosomal Storage Disorders | AMICUS THERAPEUTICS, INC. (US) | 2014-03-27 | — | — | US | disclosed |
| US-20140080871-A1 | Novel Compositions for Preventing and/or Treating Degenerative Disorders of the Central Nervous System | AMICUS THERAPEUTICS, INC. (US) | 2014-03-20 | — | — | US | disclosed |
| US-8604206-B2 | Compositions for preventing and/or treating degenerative disorders of the central nervous system | AMICUS THERAPEUTICS, INC. (US) | 2013-12-10 | — | — | US | disclosed |
| US-8604057-B2 | Compositions for preventing and/or treating lysosomal storage disorders | AMICUS THERAPEUTICS, INC. (US) | 2013-12-10 | — | — | US | disclosed |
| EP-2490533-A1 | NOVEL COMPOSITIONS FOR PREVENTING AND/OR TREATING LYSOSOMAL STORAGE DISORDERS | Amicus Therapeutics, Inc. (US) | 2012-08-29 | — | — | EP | disclosed |
| EP-2490532-A1 | NOVEL COMPOSITIONS FOR PREVENTING AND/OR TREATING DEGENERATIVE DISORDERS OF THE CENTRAL NERVOUS SYSTEM | Amicus Therapeutics, Inc. (US) | 2012-08-29 | — | — | EP | disclosed |
| WO-2011049736-A1 | NOVEL COMPOSITIONS FOR PREVENTING AND/OR TREATING DEGENERATIVE DISORDERS OF THE CENTRAL NERVOUS SYSTEM | AMICUS THERAPEUTICS, INC. (US) | 2011-04-28 | — | — | WO | disclosed |
| WO-2011049737-A1 | NOVEL COMPOSITIONS FOR PREVENTING AND/OR TREATING LYSOSOMAL STORAGE DISORDERS | AMICUS THERAPEUTICS, INC. (US) | 2011-04-28 | — | — | WO | disclosed |
| US-20110092541-A1 | NOVEL COMPOSITIONS FOR PREVENTING AND/OR TREATING DEGENERATIVE DISORDERS OF THE CENTRAL NERVOUS SYSTEM | AMICUS THERAPEUTICS, INC. (US) | 2011-04-21 | — | — | US | disclosed |
| US-20110091442-A1 | NOVEL COMPOSITIONS FOR PREVENTING AND/OR TREATING LYSOSOMAL STORAGE DISORDERS | AMICUS THERAPEUTICS, INC. (US) | 2011-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180273474-A1 | Novel Compositions For Preventing And/Or Treating Degenerative Disorders Of The Central Nervous System | GAP43, CHAT, PMP22 | GLA 1323/4885GAA 1681/4885GBA1 337/4885 |
| US-10421724-B2 | Compositions for preventing and/or treating degenerative disorders of the central nervous system | PMP22, GAP43, CHAT | GLA 1106/4885GAA 1598/4885GBA1 306/4885 |
| US-20140080871-A1 | Novel Compositions for Preventing and/or Treating Degenerative Disorders of the Central Nervous System | GAP43, CHAT, PMP22 | GLA 1323/4885GAA 1681/4885GBA1 337/4885 |
| US-20180334432-A1 | Novel Compositions for Preventing and/or Treating Lysosomal Storage Disorders | GAA, GBA1, MAN2B1 | GLA 14/4885GAA 1/4885GBA1 2/4885 |
| US-20110091442-A1 | NOVEL COMPOSITIONS FOR PREVENTING AND/OR TREATING LYSOSOMAL STORAGE DISORDERS | GAA, GBA1, MAN2B1 | GLA 14/4885GAA 1/4885GBA1 2/4885 |
| US-20110092541-A1 | NOVEL COMPOSITIONS FOR PREVENTING AND/OR TREATING DEGENERATIVE DISORDERS OF THE CENTRAL NERVOUS SYSTEM | GAP43, CHAT, PMP22 | GLA 1323/4885GAA 1681/4885GBA1 337/4885 |
| US-10035766-B2 | Compositions for preventing and/or treating lysosomal storage disorders | GAA, GBA1, MAN2B1 | GLA 11/4885GAA 1/4885GBA1 2/4885 |
| US-20140086896-A1 | Novel Compositions for Preventing and/or Treating Lysosomal Storage Disorders | GAA, GBA1, MAN2B1 | GLA 14/4885GAA 1/4885GBA1 2/4885 |
| US-20160326114-A1 | NOVEL COMPOSITIONS FOR PREVENTING AND/OR TREATING DEGENERATIVE DISORDERS OF THE CENTRAL NERVOUS SYSTEM | GAP43, CHAT, PMP22 | GLA 1323/4885GAA 1681/4885GBA1 337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.